Best Life Sciences Companies To Buy For 2014

The latest update for our Prime Time portfolio is a provider of high-performance glass for LCD televisions, computer monitors, and other information display applications, notes Charles Mizrahi, editor of Hidden Values Alert.

We like the diversification behind Corning (GLW). The company gets 36% of its revenues from Display technologies, 27% from Telecommunications, 12% from Environmental Technology, 17% from Specialty Materials (tablets/mobiles phones), and 8% from Life Sciences.

This diversification reduces the company's exposure to a specific industry, smoothing out potential bumps in the road to a particular segment.

GLW spent more than $700 million on R&D in the past 12 months (about 9% of revenue). The company continues to find applications for its glass technology.

The company can employ its proprietary technology in growth drivers such as the smartwatch and smart television markets, as well as windshields or marker boards.

GLW has more than $10.6 billion of cash and investments on its balance sheet. The company has very little short-term debt ($23 million).

5 Best Quality Stocks To Own For 2015: Amphenol Corporation(APH)

Amphenol Corporation engages in the design, manufacture, and marketing of electrical, electronic, and fiber optic connectors; interconnect systems; and coaxial and specialty cables worldwide. Its Interconnect Products and Assemblies segment produces connectors and connector assemblies primarily for the communications, aerospace, industrial, and automotive markets. This segment provides connector and cable assembly products used in communication applications; smart card acceptor and other interconnect devices used in mobile telephones; set top boxes to facilitate reading data from smart cards; fiber optic connectors used in fiber optic signal transmission; backplane and input/output connectors and assemblies used for servers and data storage devices and linking personal computers and peripheral equipment; sculptured flexible circuits used for integrating printed circuit boards; and hinge products used in mobile phone and other mobile communication devices. It also designs a nd produces radio frequency connector products and antennas used in telecommunications, computer and office equipment, instrumentation equipment, local area networks, and automotive electronics. The company?s Cable Products segment produces coaxial cable and connector products used in cable television systems, including full service cable television/telecommunication systems; radio frequency and fiber optic interconnect components for full service cable television/ telecommunication networks; and data cables and specialty cables used to connect internal components in systems with space and component configuration limitations. Amphenol Corporation markets its products directly, as well as through manufacturers? representatives and distributors to original equipment manufacturers, contract manufacturers, cable system operators, and telecommunication companies. The company was founded in 1932 and is headquartered in Wallingford, Connecticut.

Advisors' Opinion:

• [By Sally Jones] % over 12 months, Amphenol Corporation has a market cap of $12.88 billion and is traded at a P/E of 21.70. The dividend yield is 0.60%.

  The current share price is around $80.94.

  Incorporated in 1987, Amphenol Corporation designs, manufactures and markets electrical, electronic and fiber optic connectors, interconnect systems and coaxial and specialty cable. The markets for the global company's products are communication systems for the converging technologies of voice, video and data communications and a wide range of industrial applications including factory automation and motion control systems, medical and industrial instrumentation, and commercial aerospace and military applications, and many more.

  Guru Action: As of June 30, 2013, Columbia Wanger reduced its position by 0.69%, selling 29,000 shares at an average price of $76.60, gaining 7.5%.

  Columbia Wanger is the top guru stakeholder with 4,184,650 shares or 2.63% of shares outstanding.

  Over a phenomenal five-year trading history, the firm averaged a gain of 215% on 828,250 shares bought at an average price of $25.71 per share. Columbia Wanger also gained 56% selling 1,608,300 shares at an average price of $51.91 per share.

  Check out the very active insider selling and seven gurus holding APH.

  Track share pricing, revenue and net income:

  [ Enlarge Image ]

• [By Ben Levisohn]

  Competitor AVX Corp. (AVX) has gained 1.1% to $12.96, while Molex (MOLX) has dropped 0.2% to $29.28 and Amphenol (APH) has ticked up 0.3% to $76.32.

Best Life Sciences Companies To Buy For 2014: Indochine Mining Ltd (IDC)

Indochine Mining Limited is an Australia-based company developing and discovering gold and silver projects. The Company�� flagship asset is the Mt Kare gold-silver project in the highlands of Papua New Guinea (PNG). Mt Kare gold-silver project is held through its wholly owned PNG subsidiary, Summit Development Limited. The deposit lies 15 kilometers from the giant Porgera gold mine, which contains approximately 30 million ounces of gold. The Company holds two packages of exploration leases in Cambodia with potential for the discovery of gold and copper deposits. The Company�� projects in Cambodia include Kratie and Ratanakiri. Its subsidiaries include Indochine Resources Limited, Indochine Resources (Cambodia) Limited, Asia Pacific Gold & Copper Company Limited, Asia Pacific Gold & Copper (Cambodia) Limited, Aries Mining Limited, Summit Development Ltd and Positive Developments Limited. Advisors' Opinion:

• [By Analyse360Degree]

  On Thursday, International Data Corporation (IDC) came out with its 2014 First Quarter Worldwide Quarterly Tablet Tracker and shed some light on the ongoing trends in the global tablet market. The figures reported by the data giant, though not very encouraging, were strong enough to bring smile on the faces of some tablet manufacturers, but Apple (AAPL), forcing us to think if this particular consumer electronic space is getting sour for the tech giant. Let�� take a look at what�� going on.

Best Life Sciences Companies To Buy For 2014: Dynavax Technologies Corporation(DVAX)

Dynavax Technologies Corporation, a clinical-stage biopharmaceutical company, discovers and develops novel products to prevent and treat infectious diseases. The company's lead product candidate includes HEPLISAV, a Phase 3 investigational adult hepatitis B vaccine designed to provide protection with fewer doses than current licensed vaccines. It also develops Universal Flu vaccine, a Phase 1b clinical trial vaccine for influenza prevention; SD-101, a Phase Ib clinical trial hepatitis C therapy; DV-601, a Phase Ib clinical trial hepatitis B therapy; AZD1419, a preclinical asthma therapy; and DV1179, a Phase 1 trial autoimmune and inflammatory disease therapy. Dynavax Technologies Corporation has strategic alliance with GlaxoSmithKline plc to discover, develop, and commercialize DV1179 and other endosomal toll-like receptor inhibitors for diseases, such as lupus, psoriasis, and rheumatoid arthritis; and develop a TLR8 inhibitor for the treatment of multiple autoimmune and i nflammatory diseases, as well as has research and license agreement with AstraZeneca to discover and develop TLR9 agonist-based therapies for the treatment of asthma and chronic obstructive pulmonary disease. The company was founded in 1996 and is based in Berkeley, California.

Advisors' Opinion:

• [By Keith Speights]

  Dynavax (NASDAQ: DVAX  ) is a good case in point. The company's Heplisav hepatitis B vaccine looked good in clinical trials when compared to the leading vaccine on the market. Dynavax thought that the safety profile for Heplisav also compared favorably. The Food and Drug Administration even told the company that it could expand its Biologic License Application, or BLA, to include a wider age range of adults than originally planned.

• [By Rich Smith]

  Berkeley, Calif.-based Dynavax Technologies (NASDAQ: DVAX  ) has a new chief executive officer.

  On Tuesday, the vaccine manufacturer announced that current CEO Dr. Dino Dina will retire on May 1, and will be succeeded by Eddie Gray, who comes from GlaxoSmithKline, where the doctor had served as president of Pharmaceuticals, Europe, since 2008.

• [By Max Macaluso, Ph.D.]

  Shares of biotech�Dynavax Technologies� (NASDAQ: DVAX  ) �plunged 30% this morning after the company provided an update on its experimental hepatitis B vaccine Heplisav. According to its press release, the company met with the Food & Drug Administration, and the regulatory agency has stated that Dynavax simply doesn't have enough data to confirm the safety of the vaccine.

• [By Holly LaFon]

  Steven Cohen, George Soros and John Paulson are three of the most formidable investors alive today. All three of them added to one of their major holdings so far in 2012. Steven Cohen of SAC Capital Advisors added Dynavax Tech Cp (DVAX), George Soros of Soros Fund Management LLC added Acacia Research (ACTG) and John Paulson of Paulson & Co. added Novagold Resources (NG).

Best Life Sciences Companies To Buy For 2014: Potlatch Corporation(PCH)

Potlatch Corporation operates as a real estate investment trust (REIT) that owns and manages timberlands located in Arkansas, Idaho, Minnesota and Wisconsin in the United States. The Resource Management Division manages its timberlands, harvests timber, procures other wood fiber, sells logs and leases land for hunting and other recreational activity. The Real Estate Division develops and sells land parcels, as well as invests in timberlands. The Wood Products Division manufactures lumber, plywood, and particleboard in Arkansas, Idaho, Michigan, and Minnesota. This segment's products are sold to wholesalers primarily for use in home building and other construction activities. Potlatch was founded in 1903 and is headquartered in Spokane, Washington.

Advisors' Opinion:

• [By Saibus Research]

  WY and the majority of the timber, forest and paper products companies have a track record of unimpressive returns on capital, cyclical revenue and profit trends, heavy use of capital expenditures, and significant environmental regulation. We also think that WY's conversion to a REIT was a mistake. Morningstar Investment Research's Timber, Forest and Paper Products analyst Dan Rohr said it best when he rated WY and its Timber REIT peers Rayonier (RYN), Potlatch (PCH) and Plum Creek (PCL) as not possessing any economic moat. That probably explains why we only have an ancillary exposure to this industry for our proprietary portfolio based on our holdings in Brookfield Infrastructure (BIP) and Cintas (CTAS). Brookfield's Timber segment only accounts for 5% of its Fund Flows from operations and Cintas's document management business is suffering from reduced prices on recycled paper. At least Cintas Document Management only accounts for 8% of Cintas's revenue.

• [By Dan Caplinger]

  In Weyerhaeuser's report, watch for the company to discuss any plans for potential buyout activity. With tight supplies, smaller rivals Louisiana-Pacific (NYSE: LPX  ) or Potlatch (NASDAQ: PCH  ) might make good targets for the larger Weyerhaeuser or Plum Creek to look at for expansion. Even though those companies have seen their shares rise dramatically as well, it might be worth paying up in order to secure long-term assets that could produce strong growth for Weyerhaeuser.

• [By Dividends4Life]

  Potlatch Corporation (PCH) operates as a real estate investment trust (REIT) that owns and manages timberlands located in Arkansas, Idaho, Minnesota and Wisconsin. December 6th the company increased its quarterly dividend 13% to $0.35 per share. The dividend is payable December 31, 2013 to stockholders of record on December 17, 2013. The yield based on the new payout is 3.5%.

Best Life Sciences Companies To Buy For 2014: Buhler Industries Inc (BIIAF.PK)

Buhler Industries Inc. is a manufacturer of a range of agricultural equipment marketed throughout North America under three primary brand names Versatile, Allied, and Farm King. The Company�� principal products are tractors, self-propelled and pull-type sprayers, frontend loaders, grain augers, snow blowers, tillers, finishing mowers, feed processing equipment, seeding and tillage equipment and hay and forage equipment. The Company�� factories include the Winnipeg (Clarence) factory, the Morden, Manitoba factory, the Winnipeg (Regent) factory, the Bradley Steel Processors��factory, the Fargo factory, the Salem factory, the Willmar factory and the Vegreville factory. The Company�� subsidiaries include John Buhler Inc., Progressive Manufacturing Ltd., Amarillo Service & Supply Inc., Haskett Properties Inc., Buhler Versatile Inc, Haskett Investments Ltd., Buhler Finance Inc. and Buhler Ezee-On, Inc. Advisors' Opinion:

• [By Seth Barkett]

  Buhler Industries Inc. (BIIAF.PK) is headquartered in Winnipeg, Manitoba, Canada. The company was established in 1932 as an agricultural equipment manufacturer. It was purchased by John Buhler in 1969 and in 2007, Combine Factory Rostselmash Ltd. acquired 80% of the company's stock. Through steady expansion, new products and distribution channels, and acquisitions, Buhler has experienced impressive growth. With seven manufacturing plants across Canada and the United States as well as a great collection of brands like Farm King, Allied, Inland, and Versatile, this vertically-integrated manufacturer is an excellent way to invest in the global agricultural boom.

Best Life Sciences Companies To Buy For 2014: ITV PLC (ITV)

ITV Public Company Limited (ITV) is a commercial television network in the United Kingdom. t also delivers content across multiple platforms either directly or through itv.com and ITV Player. It has two segments: ITV Studios and Broadcasting & Online��segment. Its broadcasting and online segment is responsible for commissioning and scheduling programs on the ITV channels, marketing and program publicity and online rights exploitation. It derives its revenue primarily from the sale of advertising airtime and sponsorship, and other sources of revenue are from participation revenue, online advertising and the digital terrestrial multiplex, SDN. ITV Studios is an international productions business. In February 2014, ITV Plc acquired a controlling stake in DiGa Vision, the New York based independent producer of reality and scripted programming including Teen Wolf. Advisors' Opinion:

• [By Inyoung Hwang]

  ITV Plc (ITV) climbed 2.1 percent to 183.4 pence, its highest price since at least February 2004. Media buyers are indicating accelerating growth in U.K. and German advertising, according to Nomura Holdings Inc., which highlighted ITV, the owner of the U.K.�� most-watched commercial TV station, as still offering potential for price increases.

• [By Jonathan Morgan]

  ITV Plc (ITV) increased 3.7 percent to 134.2 pence, the biggest advance since February. Liberum Capital upgraded its price estimate on the U.K. broadcaster�� shares to 200 pence from 155 pence, citing ��tructurally resilient��free-to-air television advertisements and forecast growth in online and content revenue.

Best Life Sciences Companies To Buy For 2014: Prosensa Holding NV (RNA)

Prosensa Holding N.V., formerly Prosensa Holding B.V., is a biotechnology company engaged in the discovery and development of ribonucleic acid-modulating (RNA)-modulating, therapeutics for the treatment of genetic disorders. The Company�� primary focus is on rare neuromuscular and neurodegenerative disorders with a large unmet medical need, including Duchenne muscular dystrophy, myotonic dystrophy and Huntington�� disease. The Company�� clinical portfolio of RNA-based product candidates is focused on the treatment of Duchenne muscular dystrophy (DMD). The Company�� platform technology allows the development of RNA-modulating therapeutics that either interferes with splicing (exon skipping, exon inclusion, or splice mutation correction), remove mutant RNA, or block RNA expression, for different indications.

DMD is a rare, severe muscle wasting disease that occurs in up to 1 in 3,500 male births. It is commonly diagnosed between the ages of three to five, when boys begin to show signs of impaired motor development. PRO044, the Company�� product candidate, addresses a separate sub-population of DMD patients. The Company developed PRO044 using its exon-skipping technology to generate a product candidate with the same mechanism of action that is used by drisapersen.

Advisors' Opinion:

• [By Bryan Murphy]

  Anybody who knows at least something about Prosensa Holding NV (NASDAQ:RNA) will at least know the stock turned into a disaster a few weeks ago, plunging from a close of $24.00 on September 19th to a close of $7.14 on September 20th, thanks to the failure of its MS drug drisapersen, which was jointly developed with GlaxoSmithKline plc (NYSE:GSK). Such is the life of a company with only one drug anywhere close to being approved; drisapersen was in Phase 3 trials - RNA shares could have just as easily gained 70% rather than lost 70% had the drug worked.